Poliomyelitis
Description
Poliomyelitis is an acute infection that involves
the gastrointestinal tract and, occasionally, the central nervous
system. It is acquired by fecal-oral transmission.
Occurrence
In the prevaccine era, infection with poliovirus
was common, with epidemics occurring in the summer and fall in temperate
areas. The incidence of poliomyelitis declined rapidly after the
licensure of inactivated polio vaccine in 1955 and oral polio vaccine
in the 1960s. The last cases of indigenously acquired polio in the
United States occurred in 1979. Although a polio eradication program
led to elimination of polio in the Western Hemisphere, where the
last case associated with wild poliovirus was detected in 1991, outbreaks
of vaccine-derived poliovirus type 1 occurred in the Dominican Republic
and Haiti in July 2000 and in the Philippines in 2001. In spite of
these recent outbreaks, the global polio eradication initiative has
reduced the number of reported polio cases worldwide by >99% since
the mid-1980s, and worldwide eradication of the disease appears feasible
in the near future.
Risk for Travelers
Travelers to countries where polio is epidemic or
still endemic should be fully immunized. Because of polio eradication
efforts, the number of countries where travelers are at risk for
polio has decreased dramatically. Concurrent with the decline in
polio incidence, the number of polio-endemic countries decreased
from >120 in 1988 to approximately 10 in 2001. Most of the world's
population resides in areas now considered free of wild poliovirus
circulation, including the Western Hemisphere, the Western Pacific
Region (which encompasses China), and the European region. Most of
the world's remaining poliovirus transmission is in five countries:
Afghanistan, India, Pakistan, Nigeria, and Niger.
Clinical Description
Clinical manifestations of poliovirus infection
range from asymptomatic (the majority of infections) to symptomatic,
including acute flaccid paralysis of a single limb to quadriplegia,
respiratory failure, and, rarely, death.
Prevention
A person is considered to be fully immunized if
he or she has received a primary series of at least three doses of
inactivated poliovirus vaccine (IPV), live oral poliovirus (OPV),
or four doses of any combination of IPV and OPV. To eliminate the
risk of vaccine-associated paralytic poliomyelitis, OPV is no longer
recommended for routine immunization in the United States as of January
1, 2000. OPV is no longer available in this country, although it
continues to be used for global polio eradication activities.
Infants and Children
Because OPV is no longer recommended for routine
immunization in the United States, all infants and children should
receive four doses of IPV at 2, 4, and 6–18 months of age,
and 4–6 years of age. If accelerated protection is needed,
the minimum interval between doses is 4 weeks, although the preferred
interval between the second and third doses is 2 months. The minimum
age for IPV administration is 6 weeks. Infants and children who have
initiated the poliovirus vaccination series with one or more doses
of OPV should receive IPV to complete the series.
Adults
Adults who are traveling to polio-endemic areas
and are unvaccinated or whose vaccination status is unknown should
receive IPV. Two doses of IPV should be administered at intervals
of 4–8 weeks; a third dose should be administered 6–12
months after the second. If three doses of IPV cannot be administered
within the recommended intervals before protection is needed, the
following alternatives are recommended:
- If >8 weeks is available before protection is needed,
three doses of IPV should be administered at least 4 weeks apart.
- If <8 weeks but >4 weeks is available before
protection is needed, two doses of IPV should be administered at
least 4 weeks apart.
- If <4 weeks is available before protection is needed,
a single dose of IPV is recommended.
The remaining doses of vaccine should be administered
later, at the recommended intervals, if the person remains at increased
risk for poliovirus exposure. Adults who are traveling to polio-endemic
areas and have received a primary series with either IPV or OPV can
receive another dose of IPV. For adults, available data do not indicate
the need for more than a single lifetime booster dose with IPV.
Adverse Reactions
Allergy. Minor local reactions (pain and
redness) can occur following IPV. No serious adverse reactions to
IPV have been documented.
IPV should not be administered to persons who have
experienced a severe allergic (anaphylactic) reaction after a previous
dose of IPV or to streptomycin, polymyxin B, or neomycin. Because
IPV contains trace amounts of these three antibiotics, hypersensitivity
reactions can occur among persons sensitive to them.
Pregnancy. Although no adverse events of
IPV have been documented among pregnant women or their fetuses, vaccination
of pregnant women should be avoided on theoretical grounds. However,
if a pregnant woman is unvaccinated and requires immediate protection
against polio, IPV can be administered as recommended in the adult
schedule. Breast-feeding is not a contraindication to immunization
against polio.
Precautions and Contraindications
IPV may be administered to persons with diarrhea.
Minor upper respiratory illnesses with or without fever; mild to
moderate local reactions to a previous dose of IPV; current antimicrobial
therapy; and the convalescent phase of acute illness are not contraindications
for vaccination.
Immunosuppression. Administration of IPV to
immunodeficient travelers is safe, and IPV is the only polio vaccine
recommended for use in immunodeficient travelers and their household
contacts. Although a protective immune response cannot be ensured,
IPV might confer some protection to the immunodeficient person. Persons
with certain primary immunodeficiencies should avoid contact with
excreted polio vaccine virus (e.g., as may occur with a child vaccinated
with OPV within the previous 6 weeks).
— Lorraine
Alexander, Trudy Murphy
|